LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Predictors of graft failure after first detection of de novo donor-specific HLA antibodies in kidney transplant recipients.

    López Del Moral, Covadonga / Wu, Kaiyin / Naik, Marcel / Osmanodja, Bilgin / Akifova, Aylin / Lachmann, Nils / Stauch, Diana / Hergovits, Sabine / Choi, Mira / Bachmann, Friederike / Halleck, Fabian / Schrezenmeier, Eva / Schmidt, Danilo / Budde, Klemens

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

    2023  Volume 39, Issue 1, Page(s) 84–94

    Abstract: Background: De novo donor-specific antibodies (dnDSAs) may cause antibody-mediated rejection and graft dysfunction. Little is known about the clinical course after first detection of dnDSAs during screening in asymptomatic patients. We aimed to assess ... ...

    Abstract Background: De novo donor-specific antibodies (dnDSAs) may cause antibody-mediated rejection and graft dysfunction. Little is known about the clinical course after first detection of dnDSAs during screening in asymptomatic patients. We aimed to assess the value of estimated glomerular filtration rate (eGFR) and proteinuria to predict graft failure in patients with dnDSAs and their potential utility as surrogate endpoints.
    Methods: All 400 kidney transplant recipients with dnDSAs at our centre (1 March 2000-31 May 2021) were included in this retrospective study. The dates of graft loss, rejection, doubling of creatinine, ≥30% eGFR decline, proteinuria ≥500 mg/g and ≥1000 mg/g were registered from the first dnDSA appearance.
    Results: During 8.3 years of follow-up, graft failure occurred in 33.3% of patients. Baseline eGFR and proteinuria correlated with 5-year graft loss (area under the receiver operating characteristics curve 0.75 and 0.80, P < .001). Creatinine doubled after a median of 2.8 years [interquartile range (IQR) 1.5-5.0] from dnDSA and the time from doubling creatinine to graft failure was 1.0 year (IQR 0.4-2.9). Analysing eGFR reduction ≥30% as a surrogate endpoint (148/400), the time from dnDSA to this event was 2.0 years (IQR 0.6-4.2), with a positive predictive value (PPV) of 45.9% to predict graft loss, which occurred after 2.0 years (IQR 0.8-3.2). The median time from proteinuria ≥500 mg/g and ≥1000 mg/g to graft failure was identical, 1.8 years, with a PPV of 43.8% and 49.0%, respectively. Composite endpoints did not improve PPV. Multivariable analysis showed that rejection was the most important independent risk factor for all renal endpoints and graft loss.
    Conclusions: Renal function, proteinuria and rejection are strongly associated with graft failure in patients with dnDSA and may serve as surrogate endpoints.
    MeSH term(s) Humans ; Retrospective Studies ; Kidney Transplantation/adverse effects ; Isoantibodies ; Creatinine ; Graft Rejection/diagnosis ; Graft Rejection/etiology ; Graft Survival ; Biomarkers ; Proteinuria/diagnosis ; Proteinuria/etiology ; Tissue Donors ; HLA Antigens ; Transplant Recipients
    Chemical Substances Isoantibodies ; Creatinine (AYI8EX34EU) ; Biomarkers ; HLA Antigens
    Language English
    Publishing date 2023-07-06
    Publishing country England
    Document type Journal Article
    ZDB-ID 90594-x
    ISSN 1460-2385 ; 0931-0509
    ISSN (online) 1460-2385
    ISSN 0931-0509
    DOI 10.1093/ndt/gfad149
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: The natural history of

    López Del Moral, Covadonga / Wu, Kaiyin / Naik, Marcel / Osmanodja, Bilgin / Akifova, Aylin / Lachmann, Nils / Stauch, Diana / Hergovits, Sabine / Choi, Mira / Bachmann, Friederike / Halleck, Fabian / Schrezenmeier, Eva / Schmidt, Danilo / Budde, Klemens

    Frontiers in medicine

    2022  Volume 9, Page(s) 943502

    Abstract: Background: De novo: Methods: This retrospective study was designed to evaluate the natural course of dnDSA in graft function and kidney allograft survival and to assess the impact of mean fluorescence intensity (MFI) evolution as detected by annual ... ...

    Abstract Background: De novo
    Methods: This retrospective study was designed to evaluate the natural course of dnDSA in graft function and kidney allograft survival and to assess the impact of mean fluorescence intensity (MFI) evolution as detected by annual Luminex
    Results: During 8.3 years of follow-up, ABMR occurred in 24.8% and graft loss in 33.3% of the cases, especially in patients with class I and II dnDSA, and those with multiple dnDSA. We observed frequent changes in MFI with 5-year allograft survivals post-dnDSA of 74.0% in patients with MFI reduction ≥ 50%, 62.4% with fluctuating MFI (MFI reduction ≥ 50% and doubling), and 52.7% with doubling MFI (log-rank
    Conclusion: In summary, we provide an in-depth analysis of the natural course of dnDSA after kidney transplantation, first evidence for the impact of MFI evolution on graft outcomes, and describe a relevant number of patients with a stable disappearance of dnDSA, related to better allograft survival.
    Language English
    Publishing date 2022-09-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2022.943502
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Oncostatin M induces RIG-I and MDA5 expression and enhances the double-stranded RNA response in fibroblasts.

    Hergovits, Sabine / Mais, Christine / Haan, Claude / Costa-Pereira, Ana P / Hermanns, Heike M

    Journal of cellular and molecular medicine

    2017  Volume 21, Issue 11, Page(s) 3087–3099

    Abstract: Interleukin (IL)-6-type cytokines have no direct antiviral activity; nevertheless, they display immune-modulatory functions. Oncostatin M (OSM), a member of the IL-6 family, has recently been shown to induce a distinct number of classical interferon ... ...

    Abstract Interleukin (IL)-6-type cytokines have no direct antiviral activity; nevertheless, they display immune-modulatory functions. Oncostatin M (OSM), a member of the IL-6 family, has recently been shown to induce a distinct number of classical interferon stimulated genes (ISG). Most of them are involved in antigen processing and presentation. However, induction of retinoic acid-inducible gene (RIG)-I-like receptors (RLR) has not been investigated. Here we report that OSM has the capability to induce the expression of the DExD/H-Box RNA helicases RIG-I and melanoma differentiation antigen 5 (MDA5) as well as of the transcription factors interferon regulatory factor (IRF)1, IRF7 and IRF9 in primary fibroblasts. Induction of the helicases depends on tyrosine as well as serine phosphorylation of STAT1. Moreover, we could show that the OSM-induced STAT1 phosphorylation is predominantly counter-regulated by a strong STAT3-dependent SOCS3 induction, as Stat3 as well as Socs3 knock-down results in an enhanced and prolonged helicase and IRF expression. Other factors involved in regulation of STAT1 or IRF1 activity, like protein tyrosine phosphatase, non-receptor type 2 (PTPN2), promyelocytic leukaemia protein (PML) or small ubiquitin-related modifier 1 (SUMO1), play a minor role in OSM-mediated induction of RLR. Remarkably, OSM and interferon-γ (IFN-γ) synergize to mediate transcription of RLR and pre-treatment of fibroblasts with OSM fosters the type I interferon production in response to a subsequent encounter with double-stranded RNA. Together, these findings suggest that the OSM-induced JAK/STAT1 signalling is implicated in virus protection of non-professional immune cells and may cooperate with interferons to enhance RLR expression in these cells.
    MeSH term(s) Cell Line, Tumor ; DEAD Box Protein 58/antagonists & inhibitors ; DEAD Box Protein 58/genetics ; DEAD Box Protein 58/immunology ; Fibroblasts/cytology ; Fibroblasts/drug effects ; Fibroblasts/metabolism ; Gene Expression Regulation ; Humans ; Immunity, Innate ; Interferon Regulatory Factor-1/genetics ; Interferon Regulatory Factor-1/immunology ; Interferon Regulatory Factor-7/genetics ; Interferon Regulatory Factor-7/immunology ; Interferon-Induced Helicase, IFIH1/antagonists & inhibitors ; Interferon-Induced Helicase, IFIH1/genetics ; Interferon-Induced Helicase, IFIH1/immunology ; Interferon-Stimulated Gene Factor 3, gamma Subunit/genetics ; Interferon-Stimulated Gene Factor 3, gamma Subunit/immunology ; Interferon-gamma/pharmacology ; Interleukin-6/pharmacology ; Leukemia Inhibitory Factor/pharmacology ; Leukemia Inhibitory Factor Receptor alpha Subunit/genetics ; Leukemia Inhibitory Factor Receptor alpha Subunit/immunology ; Lipopolysaccharides/pharmacology ; Lung/cytology ; Lung/drug effects ; Lung/metabolism ; Oncostatin M/pharmacology ; Osteoblasts/cytology ; Osteoblasts/drug effects ; Osteoblasts/metabolism ; Primary Cell Culture ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism ; Receptors, Immunologic ; STAT1 Transcription Factor/genetics ; STAT1 Transcription Factor/immunology ; STAT3 Transcription Factor/genetics ; STAT3 Transcription Factor/immunology ; Signal Transduction ; Skin/cytology ; Skin/drug effects ; Skin/metabolism ; Suppressor of Cytokine Signaling 3 Protein/genetics ; Suppressor of Cytokine Signaling 3 Protein/immunology
    Chemical Substances IL6 protein, human ; IRF1 protein, human ; IRF7 protein, human ; IRF9 protein, human ; Interferon Regulatory Factor-1 ; Interferon Regulatory Factor-7 ; Interferon-Stimulated Gene Factor 3, gamma Subunit ; Interleukin-6 ; LIF protein, human ; LIFR protein, human ; Leukemia Inhibitory Factor ; Leukemia Inhibitory Factor Receptor alpha Subunit ; Lipopolysaccharides ; RNA, Small Interfering ; Receptors, Immunologic ; SOCS3 protein, human ; STAT1 Transcription Factor ; STAT1 protein, human ; STAT3 Transcription Factor ; STAT3 protein, human ; Suppressor of Cytokine Signaling 3 Protein ; Oncostatin M (106956-32-5) ; Interferon-gamma (82115-62-6) ; RIGI protein, human (EC 3.6.1.-) ; IFIH1 protein, human (EC 3.6.1.-) ; DEAD Box Protein 58 (EC 3.6.4.13) ; Interferon-Induced Helicase, IFIH1 (EC 3.6.4.13)
    Language English
    Publishing date 2017-05-30
    Publishing country England
    Document type Journal Article
    ZDB-ID 2074559-X
    ISSN 1582-4934 ; 1582-4934 ; 1582-1838
    ISSN (online) 1582-4934
    ISSN 1582-4934 ; 1582-1838
    DOI 10.1111/jcmm.13221
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Endocytosis of pro-inflammatory cytokine receptors and its relevance for signal transduction.

    Hermanns, Heike M / Wohlfahrt, Julia / Mais, Christine / Hergovits, Sabine / Jahn, Daniel / Geier, Andreas

    Biological chemistry

    2016  Volume 397, Issue 8, Page(s) 695–708

    Abstract: The pro-inflammatory cytokines tumor necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6) are key players of the innate and adaptive immunity. Their activity needs to be tightly controlled to allow the initiation of an appropriate immune ... ...

    Abstract The pro-inflammatory cytokines tumor necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6) are key players of the innate and adaptive immunity. Their activity needs to be tightly controlled to allow the initiation of an appropriate immune response as defense mechanism against pathogens or tissue injury. Excessive or sustained signaling of either of these cytokines leads to severe diseases, including rheumatoid arthritis, inflammatory bowel diseases (Crohn's disease, ulcerative colitis), steatohepatitis, periodic fevers and even cancer. Studies carried out in the last 30 years have emphasized that an elaborate control system for each of these cytokines exists. Here, we summarize what is currently known about the involvement of receptor endocytosis in the regulation of these pro-inflammatory cytokines' signaling cascades. Particularly in the last few years it was shown that this cellular process is far more than a mere feedback mechanism to clear cytokines from the circulation and to shut off their signal transduction.
    MeSH term(s) Animals ; Endocytosis ; Endosomes/metabolism ; Humans ; Inflammation Mediators/metabolism ; Receptors, Cytokine/metabolism ; Signal Transduction
    Chemical Substances Inflammation Mediators ; Receptors, Cytokine
    Language English
    Publishing date 2016-08-01
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 1334659-3
    ISSN 1437-4315 ; 1431-6730 ; 1432-0355
    ISSN (online) 1437-4315
    ISSN 1431-6730 ; 1432-0355
    DOI 10.1515/hsz-2015-0277
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Book ; Online ; Thesis: Relevanz der gp130 Endozytose bei der Maturierung und Differenzierung dendritischer Zellen sowie Charakterisierung des molekularen Mechanismus der OSM-vermittelten Induktion antiviraler Gene ; Gutachter: Heike M. Hermanns, Manfred B. Lutz

    Hergovits, Sabine [Verfasser] / Hermanns, Heike M. [Gutachter] / Lutz, Manfred B. [Gutachter]

    2017  

    Author's details Sabine Hergovits [geb. Walter
    Keywords Biowissenschaften, Biologie ; Life Science, Biology
    Subject code sg570
    Language German
    Publisher Universität Würzburg
    Publishing place Würzburg
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  6. Article ; Online: The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by α-PD-L1 or α-IL6 antibodies.

    Rolvering, Catherine / Zimmer, Andreas D / Ginolhac, Aurélien / Margue, Christiane / Kirchmeyer, Mélanie / Servais, Florence / Hermanns, Heike M / Hergovits, Sabine / Nazarov, Petr V / Nicot, Nathalie / Kreis, Stephanie / Haan, Serge / Behrmann, Iris / Haan, Claude

    Journal of leukocyte biology

    2018  Volume 104, Issue 5, Page(s) 969–985

    Abstract: Interleukin-27 (IL27) is a type-I cytokine of the IL6/IL12 family and is predominantly secreted by activated macrophages and dendritic cells. We show that IL27 induces STAT factor phosphorylation in cancerous cell lines of different tissue origin. IL27 ... ...

    Abstract Interleukin-27 (IL27) is a type-I cytokine of the IL6/IL12 family and is predominantly secreted by activated macrophages and dendritic cells. We show that IL27 induces STAT factor phosphorylation in cancerous cell lines of different tissue origin. IL27 leads to STAT1 phosphorylation and recapitulates an IFN-γ-like response in the microarray analyses, with up-regulation of genes involved in antiviral defense, antigen presentation, and immune suppression. Like IFN-γ, IL27 leads to an up-regulation of TAP2 and MHC-I proteins, which mediate increased tumor immune clearance. However, both cytokines also upregulate proteins such as PD-L1 (CD274) and IDO-1, which are associated with immune escape of cancer. Interestingly, differential expression of these genes was observed within the different cell lines and when comparing IL27 to IFN-γ. In coculture experiments of hepatocellular carcinoma (HCC) cells with peripheral blood mononuclear cells, pre-treatment of the HCC cells with IL27 resulted in lowered IL2 production by anti-CD3/-CD28 activated T-lymphocytes. Addition of anti-PD-L1 antibody, however, restored IL2 secretion. The levels of other T
    MeSH term(s) B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Cell Line, Tumor ; Humans ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/immunology ; Interleukins/immunology ; Neoplasms/immunology ; STAT1 Transcription Factor/immunology ; Signal Transduction/immunology ; Tumor Escape/immunology
    Chemical Substances B7-H1 Antigen ; CD274 protein, human ; IL6 protein, human ; Interleukin-6 ; Interleukins ; MYDGF protein, human ; STAT1 Transcription Factor ; STAT1 protein, human
    Language English
    Publishing date 2018-07-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 605722-6
    ISSN 1938-3673 ; 0741-5400
    ISSN (online) 1938-3673
    ISSN 0741-5400
    DOI 10.1002/JLB.MA1217-495R
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Novel GM-CSF signals via IFN-γR/IRF-1 and AKT/mTOR license monocytes for suppressor function.

    Ribechini, Eliana / Hutchinson, James A / Hergovits, Sabine / Heuer, Marion / Lucas, Jörg / Schleicher, Ulrike / Jordán Garrote, Ana-Laura / Potter, Sarah J / Riquelme, Paloma / Brackmann, Heike / Müller, Nora / Raifer, Hartmann / Berberich, Ingolf / Huber, Magdalena / Beilhack, Andreas / Lohoff, Michael / Bogdan, Christian / Eyrich, Matthias / Hermanns, Heike M /
    Geissler, Edward K / Lutz, Manfred B

    Blood advances

    2017  Volume 1, Issue 14, Page(s) 947–960

    Abstract: Granulocyte-macrophage colony-stimulating factor (GM-CSF) controls proliferation and survival of myeloid cells including monocytes. Here, we describe a time-dependent licensing process driven by GM-CSF in murine ... ...

    Abstract Granulocyte-macrophage colony-stimulating factor (GM-CSF) controls proliferation and survival of myeloid cells including monocytes. Here, we describe a time-dependent licensing process driven by GM-CSF in murine Ly6C
    Language English
    Publishing date 2017-06-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2876449-3
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2017006858
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top